Private Plan Outlook Alberta Blue Cross's 2026 drug pipeline report identifies GLP-1 therapies as a major cost driver, stating that while a semaglutide generic is expected in mid-2026, overall GLP-1 therapy plan spend is unlikely to decline in future years due to growing use and continued expansion of GLP-1 therapies [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php]
Conclusions In the SURMOUNT-1 study, tirzepatide was cost-efficient in the UK for weight management, demonstrating favourable economic outcomes relative to its efficacy in reducing body weight and improving BMI
In short, cagrilintide adds one non-incretin appetite axis, while retatrutide stacks three metabolic signals into one molecule
It can make the skin appear fresher and more luminous
Oh, I almost forgot
Lake Mary Laser Hair Removal Serving University of Central Florida students At CSLC Lake Mary, smooth, hair-free skin is a favorite for students and adults alike